<?xml version='1.0' encoding='utf-8'?>
<document id="25438721"><sentence text="Evaluation of the potential for pharmacokinetic drug-drug interaction between armodafinil and carbamazepine in healthy adults."><entity charOffset="78-89" id="DDI-PubMed.25438721.s1.e0" text="armodafinil" /><entity charOffset="94-107" id="DDI-PubMed.25438721.s1.e1" text="carbamazepine" /><pair ddi="false" e1="DDI-PubMed.25438721.s1.e0" e2="DDI-PubMed.25438721.s1.e0" /><pair ddi="false" e1="DDI-PubMed.25438721.s1.e0" e2="DDI-PubMed.25438721.s1.e1" /></sentence><sentence text="Polypharmacy is common in psychiatry practice and can lead to an increased risk of drug interactions" /><sentence text=" Armodafinil, a wakefulness-promoting agent, has been studied as adjunctive therapy for the treatment of major depressive episodes associated with bipolar I disorder"><entity charOffset="1-12" id="DDI-PubMed.25438721.s3.e0" text="Armodafinil" /></sentence><sentence text=" Armodafinil and the mood stabilizer carbamazepine are both inducers of and substrates for cytochrome P450 (CYP3A4)"><entity charOffset="1-12" id="DDI-PubMed.25438721.s4.e0" text="Armodafinil" /><entity charOffset="37-50" id="DDI-PubMed.25438721.s4.e1" text="carbamazepine" /><pair ddi="false" e1="DDI-PubMed.25438721.s4.e0" e2="DDI-PubMed.25438721.s4.e0" /><pair ddi="false" e1="DDI-PubMed.25438721.s4.e0" e2="DDI-PubMed.25438721.s4.e1" /></sentence><sentence text=" This study was designed to evaluate the bidirectional carbamazepine-armodafinil pharmacokinetic drug-drug interaction"><entity charOffset="55-68" id="DDI-PubMed.25438721.s5.e0" text="carbamazepine" /><entity charOffset="69-80" id="DDI-PubMed.25438721.s5.e1" text="armodafinil" /><pair ddi="false" e1="DDI-PubMed.25438721.s5.e0" e2="DDI-PubMed.25438721.s5.e0" /><pair ddi="false" e1="DDI-PubMed.25438721.s5.e0" e2="DDI-PubMed.25438721.s5.e1" /></sentence><sentence text="" /><sentence text="This was an open-label, single-center study conducted in healthy adult men" /><sentence text=" Subjects assigned to group 1 received a dose of carbamazepine (200 mg) alone and a dose after pretreatment with daily dosing of armodafinil (titrated to 250 mg/d)"><entity charOffset="49-62" id="DDI-PubMed.25438721.s8.e0" text="carbamazepine" /><entity charOffset="129-140" id="DDI-PubMed.25438721.s8.e1" text="armodafinil" /><pair ddi="false" e1="DDI-PubMed.25438721.s8.e0" e2="DDI-PubMed.25438721.s8.e0" /><pair ddi="false" e1="DDI-PubMed.25438721.s8.e0" e2="DDI-PubMed.25438721.s8.e1" /></sentence><sentence text=" Subjects assigned to group 2 received a dose of armodafinil (250 mg) alone and a dose after pretreatment with carbamazepine BID (titrated to 400 mg/d)"><entity charOffset="49-60" id="DDI-PubMed.25438721.s9.e0" text="armodafinil" /><entity charOffset="111-124" id="DDI-PubMed.25438721.s9.e1" text="carbamazepine" /><pair ddi="false" e1="DDI-PubMed.25438721.s9.e0" e2="DDI-PubMed.25438721.s9.e0" /><pair ddi="false" e1="DDI-PubMed.25438721.s9.e0" e2="DDI-PubMed.25438721.s9.e1" /></sentence><sentence text=" Pharmacokinetic parameters for carbamazepine, armodafinil, and their major circulating metabolites were determined when dosed alone and after pretreatment with the other drug"><entity charOffset="32-45" id="DDI-PubMed.25438721.s10.e0" text="carbamazepine" /><entity charOffset="47-58" id="DDI-PubMed.25438721.s10.e1" text="armodafinil" /><pair ddi="false" e1="DDI-PubMed.25438721.s10.e0" e2="DDI-PubMed.25438721.s10.e0" /><pair ddi="false" e1="DDI-PubMed.25438721.s10.e0" e2="DDI-PubMed.25438721.s10.e1" /></sentence><sentence text=" The safety and tolerability of armodafinil and carbamazepine were also assessed throughout the study"><entity charOffset="32-43" id="DDI-PubMed.25438721.s11.e0" text="armodafinil" /><entity charOffset="48-61" id="DDI-PubMed.25438721.s11.e1" text="carbamazepine" /><pair ddi="false" e1="DDI-PubMed.25438721.s11.e0" e2="DDI-PubMed.25438721.s11.e0" /><pair ddi="false" e1="DDI-PubMed.25438721.s11.e0" e2="DDI-PubMed.25438721.s11.e1" /></sentence><sentence text="" /><sentence text="Eighty-one subjects enrolled in the study (group 1 = 40; group 2 = 41), of whom 79 (group 1 = 40; group 2 = 39) were evaluable for pharmacokinetic analysis and 80 (group 1 = 40; group 2 = 40) were evaluable for safety analysis" /><sentence text=" In group 1, pretreatment with armodafinil reduced systemic exposure to carbamazepine by 12% for Cmax and 25% for AUC (based on comparison of geometric means)"><entity charOffset="31-42" id="DDI-PubMed.25438721.s14.e0" text="armodafinil" /><entity charOffset="72-85" id="DDI-PubMed.25438721.s14.e1" text="carbamazepine" /><pair ddi="false" e1="DDI-PubMed.25438721.s14.e0" e2="DDI-PubMed.25438721.s14.e0" /><pair ddi="false" e1="DDI-PubMed.25438721.s14.e0" e2="DDI-PubMed.25438721.s14.e1" /></sentence><sentence text=" Similarly, in group 2, pretreatment with carbamazepine reduced systemic exposure to armodafinil by 11% for Cmax and 37% for AUC"><entity charOffset="42-55" id="DDI-PubMed.25438721.s15.e0" text="carbamazepine" /></sentence><sentence text=" Systemic exposure to the metabolites of these agents that are formed via CYP3A4 were increased after pretreatment in each group" /><sentence text=" There were no new or unexpected adverse events" /><sentence text="" /><sentence text="Systemic exposure to both carbamazepine and armodafinil was reduced after pretreatment with the other drug; systemic exposure to the metabolites of each drug, which are formed via CYP3A4, was increased"><entity charOffset="26-39" id="DDI-PubMed.25438721.s19.e0" text="carbamazepine" /><entity charOffset="44-55" id="DDI-PubMed.25438721.s19.e1" text="armodafinil" /><pair ddi="false" e1="DDI-PubMed.25438721.s19.e0" e2="DDI-PubMed.25438721.s19.e0" /><pair ddi="false" e1="DDI-PubMed.25438721.s19.e0" e2="DDI-PubMed.25438721.s19.e1" /></sentence><sentence text=" These changes were consistent with the induction of CYP3A4" /><sentence text=" Both drugs were generally safe and well tolerated alone and in combination under the conditions studied" /><sentence text=" Dose adjustment may be required when initiating or discontinuing armodafinil and carbamazepine cotherapy"><entity charOffset="66-77" id="DDI-PubMed.25438721.s22.e0" text="armodafinil" /><entity charOffset="82-95" id="DDI-PubMed.25438721.s22.e1" text="carbamazepine" /><pair ddi="false" e1="DDI-PubMed.25438721.s22.e0" e2="DDI-PubMed.25438721.s22.e0" /><pair ddi="false" e1="DDI-PubMed.25438721.s22.e0" e2="DDI-PubMed.25438721.s22.e1" /></sentence><sentence text="" /></document>